Cambridge Investment Research Advisors’s Vir Biotechnology VIR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Buy	10,455 +100	+1%	+$951	﹤0.01%	3926
2026 Q1	$93K	Hold	10,355	–	–	﹤0.01%	3804
2025 Q4	$62K	Buy	+10,355	New	+$61.7K	﹤0.01%	3743
2022 Q4	–	Sell	-11,426	Closed	-$220K	–	3217
2022 Q3	$220K	Buy	+11,426	New	+$290K	﹤0.01%	2624
2022 Q1	–	Sell	-10,225	Closed	-$428K	–	3322
2021 Q4	$428K	Sell	10,225 -4,565	-31%	-$179K	﹤0.01%	2240
2021 Q3	$644K	Buy	14,790 +4,270	+41%	+$185K	﹤0.01%	1848
2021 Q2	$497K	Buy	10,520 +150	+1%	+$6.82K	﹤0.01%	2070
2021 Q1	$532K	Buy	+10,370	New	+$559K	﹤0.01%	1865

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cambridge Investment Research Advisors's VIR Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Vir Biotechnology (VIR) stake by 0.97% in Q2 2026, buying an estimated $951 and bringing the position to 10,455 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

Cambridge Investment Research Advisors first reported a position in VIR in Q1 2021 and has held it in 8 quarters since. The position peaked at $644K in Q3 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Cambridge Investment Research Advisors held 10,455 shares of Vir Biotechnology worth $107K as of Q2 2026.
Cambridge Investment Research Advisors bought 100 Vir Biotechnology shares in Q2 2026, an estimated $951.
Vir Biotechnology made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3926 holding.
Cambridge Investment Research Advisors first reported a position in Vir Biotechnology in Q1 2021 and has held it in 8 quarters since.
Cambridge Investment Research Advisors's Vir Biotechnology position peaked at $644K in Q3 2021.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.